Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Retained Earnings (2021 - 2025)

Amylyx Pharmaceuticals (AMLX) has 5 years of Retained Earnings data on record, last reported at -$751.4 million in Q4 2025.

  • For Q4 2025, Retained Earnings fell 23.86% year-over-year to -$751.4 million; the TTM value through Dec 2025 reached -$751.4 million, down 23.86%, while the annual FY2025 figure was -$751.4 million, 23.86% down from the prior year.
  • Retained Earnings reached -$751.4 million in Q4 2025 per AMLX's latest filing, down from $815000.0 in the prior quarter.
  • Across five years, Retained Earnings topped out at $815000.0 in Q3 2025 and bottomed at -$751.4 million in Q4 2025.
  • Average Retained Earnings over 5 years is -$245.2 million, with a median of -$102.2 million recorded in 2022.
  • Peak YoY movement for Retained Earnings: plummeted 3935877.78% in 2022, then surged 100.14% in 2025.
  • A 5-year view of Retained Earnings shows it stood at $9000.0 in 2021, then tumbled by 3935877.78% to -$354.2 million in 2022, then skyrocketed by 100.06% to $197000.0 in 2023, then plummeted by 308065.48% to -$606.7 million in 2024, then decreased by 23.86% to -$751.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were -$751.4 million in Q4 2025, $815000.0 in Q3 2025, and -$684.0 million in Q2 2025.